Astellas Pharma R&D Day Summary Company Overview - **Company**: Astellas Pharma - **Event**: R&D Day - **Key Speakers**: Naoki Okamura (CEO), Tadaaki Taniguchi (CRDO) Core Industry Focus - **Primary Focus Areas**: 1. Immuno-oncology 2. Targeted protein degradation 3. Blindness and regeneration 4. Genetic regulation Key Points and Arguments Vision and Strategy - Astellas aims to transform innovative science into value for patients, focusing on outcomes that matter to patients and the costs to the healthcare system [3][4] - The **Focus Area Approach** is employed to address high unmet medical needs, linking biology, modality, and technology [3][4] R&D Progress - Achieved proof of concept (POC) for three assets: ASP 2138, ASP 7317, and zitidagresib (ASP 3082) [5] - Over the past five years, Astellas accelerated its pipeline, achieving 12 phase II first subject doses and initiating one new phase III trial [5] - Terminated 21 clinical stage programs to reallocate resources to higher value assets, improving overall pipeline quality [6] Financial and Operational Strategy - Focus on maximizing sales of strategic brands to mitigate revenue decline from XTANDI's loss of exclusivity [8] - Implementing a new end-to-end operational model to enhance productivity and integrate research, development, commercialization, and lifecycle management [9] Pipeline Development - Building a robust pipeline with strategic brands, flagship programs, and follow-on programs [9][10] - Examples include the prostate cancer franchise and the acquisition of IZERVAY for geographic atrophy in age-related macular degeneration [10] Specific Program Updates - **Setidegrasib**: A targeted protein degrader for solid tumors with KRAS G12D mutations, showing promising results in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) [24][25] - ORR of 58.3% in PDAC and 37.5% in NSCLC with ongoing phase III trials [26][28] - **ASP2138**: A bispecific antibody targeting claudin 18.2 in gastric cancer, preparing for phase III trials [30] - **ASP7317**: Achieved POC for severe visual impairment in geographic atrophy, moving towards phase III [34] Future Outlook - Astellas plans to transform its R&D organization and governance structure to enhance productivity from 2024 to 2026, aiming for significant improvements in R&D productivity by 2030 to 2034 [15][36] - Continuous investment in cutting-edge technologies, including AI and robotics, to accelerate drug discovery and clinical trials [20][21] Additional Important Insights - Astellas emphasizes the importance of portfolio discipline, making strategic decisions to discontinue low-value projects [6][45] - The company is actively collaborating with external partners and academia to enhance its R&D capabilities [22] - Astellas aims to maintain a 30% operating margin sustainably while investing in R&D and managing expenses effectively [53][58] This summary encapsulates the key points discussed during Astellas Pharma's R&D Day, highlighting the company's strategic focus, R&D progress, and future outlook in the pharmaceutical industry.

Astellas R&D Day Pioneering science to change tomorrow March 31, 2026 1 ©2026 ASTELLAS PHARMA INC. AND ITS AFFILIATES. Cautionary statement regarding forward-looking information In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas Pharma. These statements are based on management's current assumptions and beliefs in light of the information c ...

Core Viewpoint - Nurix Therapeutics is advancing its research pipeline in targeted protein degradation medicines, with significant presentations scheduled at the AACR 2026 Annual Meeting, showcasing its scientific leadership and potential therapeutic targets in oncology [1][2]. Group 1: Presentations at AACR 2026 - Two oral presentations and three poster presentations will highlight Nurix's research pipeline, focusing on CBL-B, Aurora kinase A (AURKA), and mutant BRAF as therapeutic targets [1][2]. - Gwenn Hansen, Ph.D., the chief scientific officer, will present on induced proximity pharmacology, emphasizing the advancements in targeted protein degradation [3]. Group 2: Oral Presentation Details - The first oral presentation titled "Designing Effective Degrader Therapeutics: What Early Clinical Experience Has Taught Us" will be delivered by Gwenn Hansen on April 22, 2026 [4]. - The second oral presentation will focus on the discovery of CBL-B intramolecular glue inhibitors that enhance T cell activation and suppress tumor growth, presented by Fred Cohen, Ph.D., on April 21, 2026 [4]. Group 3: Poster Presentation Details - The poster titled "NRX-4972, a selective, oral, Aurora kinase A degrader" will be presented by Ryan Rountree, Ph.D., demonstrating increased efficacy in SCLC tumor models [5]. - Another poster on "NRX-0305, an orally bioavailable, CNS penetrant pan-mutant BRAF degrader" will be presented by Sasha Borodovsky, Ph.D., showcasing robust efficacy in intracranial models of melanoma brain metastasis [5]. - A third poster will discuss NRX-0305's efficacy across various BRAF-mutant cancers, presented by Ya-Wen Lu, Ph.D. [5]. Group 4: Product Information - NX-1607 is an investigational oral inhibitor of CBL-B, targeting immuno-oncology indications and showing promise in reversing T cell exhaustion in preclinical studies [6]. - NRX-0305 is a potent, selective, orally bioavailable pan-mutant BRAF degrader, demonstrating anti-tumor activity in various models, including CNS disease [7]. - NRX-4972 is a CNS-penetrant, orally bioavailable degrader of AURKA, designed to overcome limitations of traditional inhibitors in treating solid tumors [8]. Group 5: Company Overview - Nurix Therapeutics is focused on the discovery and commercialization of targeted protein degradation medicines, aiming to improve treatment options for cancer and autoimmune diseases [9]. - The company has a robust pipeline, including degraders of Bruton's tyrosine kinase (BTK) and inhibitors of CBL-B, with collaborations with major pharmaceutical companies like Gilead and Sanofi [9].

Kymera Therapeutics FY Conference Summary Company Overview - **Company**: Kymera Therapeutics (NasdaqGM:KYMR) - **Founded**: Nearly ten years ago, focusing on targeted protein degradation technology - **Team Size**: Approximately 250 employees with expertise in lead discovery and chemistry [3][4] Pipeline and Programs - **Focus**: Initially on oncology and immunology, now primarily on immunology targets due to early successes [4] - **Annual Program Introduction**: Aiming to introduce one new program each year, with the next expected in the second half of 2026 [6] - **STAT6 Program**: Significant progress with de-risking data released in June and December, showing 94%-98% degradation in patient cohorts [11][12] - **Atopic Dermatitis and Asthma Trials**: Ongoing trials with plans to complete enrollment by the end of 2026 and share data by mid-2027 [16][17] Competitive Landscape - **Differentiation**: Kymera's unique target selection approach focuses on high-value targets with significant unmet needs, differentiating it from competitors [8][9] - **Market Opportunity**: Potential to provide an oral alternative to existing injectable biologics like Dupixent, which is currently a significant player in the market [14][15] Clinical Data and Expectations - **Clinical Endpoints**: Positive results in EASI scores and quality of life measures for atopic dermatitis patients, with ongoing studies for asthma [13][29] - **Phase 2 Studies**: Aiming to translate early results into broader trials, with a focus on selecting a single dose for Phase 3 studies [21][22] - **IRF5 Program**: Anticipated data from healthy volunteers by the end of 2026, with plans to move into patient studies, likely targeting lupus [37][42] Strategic Development - **Expansion Strategy**: Plans to pursue multiple Phase 3 studies across various indications, prioritizing those with the largest market potential [31][32] - **Pediatric Population**: Aiming to expedite access to younger patients, recognizing the significant unmet need in this demographic [34] Financial Position - **Capitalization**: $1.6 billion on the balance sheet, providing a runway into 2029 to support ongoing and future development [36] Target Selection Criteria - **Focus on Immunology**: Approximately 80% of ongoing work is in immunology, targeting areas with significant unmet needs and potential for oral administration [47][48] Partnership Strategy - **Integration Focus**: Kymera aims to be a fully integrated biotech company, with partnerships not a priority in the near term, especially for the STAT6 program [51][52] Conclusion - **Outlook**: Kymera Therapeutics is positioned to leverage its unique technology and strong financial backing to address significant unmet needs in immunology, with a focus on developing oral alternatives to existing therapies. The company is committed to executing its clinical development strategy and expanding its pipeline effectively.

Kymera Therapeutics Conference Call Summary Company Overview - **Company**: Kymera Therapeutics (NasdaqGM:KYMR) - **Focus**: Development of targeted protein degradation therapies for autoimmune diseases, particularly through the use of STAT6 degrader, KT-621 [1][3][4] Core Industry Insights - **Immunology Focus**: Kymera has concentrated efforts in immunology due to the success of biologics in treating diseases like psoriasis, atopic dermatitis (AD), inflammatory bowel disease (IBD), and lupus [5][6] - **Targeting Undrugged Pathways**: The company aims to develop drugs that target intracellular pathways that have historically been undrugged, leveraging human genetics validation [4][6] Key Product Insights - **KT-621**: - A drug developed to degrade STAT6, showing preclinical efficacy comparable to IL-4 receptor blockers like Dupilumab [7][10] - Phase 1b study results indicated a 63% median reduction in EASI (Eczema Area and Severity Index) after four weeks, with significant biomarker impacts [12][10] - The drug demonstrated a 94-98% degradation of STAT6, which is critical for efficacy [18][19] - Ongoing Phase 2b studies in AD and asthma, with results expected in 2027 [10][10] Clinical Data Highlights - **Phase 1b Study Results**: - Impact on type 2 inflammation biomarkers, including FeNO (Fractional Exhaled Nitric Oxide) reduction of 50%-60% in asthma patients [8][42] - Robust activity in clinical endpoints such as itch and sleeplessness, competitive with existing biologics [48] - **Safety Profile**: - Early data suggests a safety profile similar to placebo, with no significant adverse findings in preclinical studies [23][26] Future Development Plans - **Phase 2b Studies**: - Global dose-ranging studies for KT-621 in AD (200 patients, 16 weeks) and asthma (12 weeks) [10][10] - Focus on selecting the right phase 3 dose based on these studies [10] - **IRF5 Program**: - Upcoming Phase 1 data expected in the second half of the year, targeting autoimmune diseases like lupus, IBD, and rheumatoid arthritis [55][56] - Aiming for 85%-90% degradation of IRF5 to achieve maximal pharmacological effects [59] Market Context - **Competitive Landscape**: - The AD market is becoming increasingly competitive with many drugs in development, necessitating differentiation [51] - Kymera's approach focuses on leveraging human genetics and preclinical data to select indications with high unmet needs [62][63] Additional Considerations - **Regulatory and Clinical Strategy**: - Emphasis on managing placebo response variability in clinical trials through diverse patient populations and rigorous trial conduct [54] - **Future Programs**: - Interest in autoantibody-driven diseases and TH1 type inflammation, with plans to announce new programs once development candidates are ready [68][69] Conclusion - Kymera Therapeutics is positioned to potentially revolutionize treatment for autoimmune diseases through innovative approaches in protein degradation, with promising early clinical data and a robust pipeline aimed at addressing significant unmet medical needs in the immunology space [1][3][4]

Core Insights - Bristol Myers Squibb (BMY) reported positive interim results from the late-stage SUCCESSOR-2 study, evaluating mezigdomide in combination with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma (RRMM) patients [1][3] Group 1: Study Results - The SUCCESSOR-2 trial demonstrated that oral mezigdomide combined with carfilzomib and dexamethasone significantly improved progression-free survival compared to carfilzomib and dexamethasone alone in RRMM patients [3][10] - This study marks the first positive phase III trial for mezigdomide and the second successful phase III study for BMY's CELMoD program, reinforcing confidence in the company's targeted protein degradation platform [4][10] Group 2: Market Context - Despite advancements in treatment, multiple myeloma remains incurable, leading to strong demand for new therapies, particularly those effective after prior treatments [5] - Mezigdomide is designed to be more effective than earlier immunomodulatory drugs, potentially offering a convenient oral treatment option for patients previously treated with therapies like anti-CD38 antibodies and lenalidomide [6] Group 3: Company Strategy - BMY is looking to diversify its portfolio as its legacy drugs, such as Revlimid, face generic competition, which pressures revenue growth [7] - The successful development of mezigdomide could significantly boost the company's position in the market [7][10] - BMY's targeted protein degradation platform includes various investigational approaches aimed at tackling disease-driving proteins previously considered difficult to target [8] Group 4: Future Prospects - Patients in the SUCCESSOR-2 study will continue to be monitored for overall survival and long-term safety outcomes, with data to be presented at future medical meetings [4] - Mezigdomide is also being evaluated in other combinations in ongoing phase III studies, indicating a robust pipeline for BMY [9]

Summary of C4 Therapeutics FY Conference Call Company Overview - C4 Therapeutics is a targeted protein degradation company focused on developing medicines for areas of high unmet need, particularly in oncology and inflammation [3][5] Key Programs - **Cemsidomide**: - An IKZF1/3 degrader targeting multiple myeloma, currently in a Phase 2 study called MOMENTUM, which started dosing patients last month [3][4] - Expected to start a Phase 1B study in combination with elranatamab (a BiTE from Pfizer) in Q2 [4] - Data from the first-in-human study showed a 53% response rate in heavily pre-treated patients, indicating a foundational role for targeting IKZF1/3 [12][13] - Positioned as a potential best-in-class drug due to optimized catalytic activity, selectivity, and pharmacokinetics [10][11] - **CFT8919**: - An EGFR L858R degrader for non-small cell lung cancer, currently in a Phase 1 study in China, with data expected this month [4][88] - Aims to improve outcomes for patients with the L858R driver mutation [89] Financial Position - C4 Therapeutics reported a strong balance sheet with nearly $300 million at the end of the year, providing runway through the end of 2028 [6] Upcoming Milestones - Key milestones include: - Early data look from the MOMENTUM study in the second half of 2027 [6] - Potential Phase 3 study with the BiTE combination [6] Clinical Trial Insights - The MOMENTUM trial will be conducted in the U.S. and Western Europe, with eligibility criteria focusing on patients with fourth-line plus therapy [18] - The trial aims for regulatory intent, with independent safety data monitoring to ensure data integrity [25][51] - Anticipated response rate for the trial is 40% or greater, with a duration of response expected to be at least six months [36][40] Competitive Landscape - Cemsidomide is positioned to differentiate itself from other therapies, particularly in post-BCMA treatment settings, where it has shown significant activity [49][50] - The drug's unique pharmacokinetics allow for a 14-day on, 14-day off dosing schedule, which is pharmacologically optimized [79][84] Collaboration and Discovery Efforts - C4 Therapeutics is collaborating with Roche, Merck KGaA, and Biogen to develop degraders against targets of interest [5] - The company is also exploring internal programs focused on inflammation, neuroinflammation, and neurodegeneration [5] Conclusion - C4 Therapeutics is positioned for significant growth with its innovative drug candidates and strong financial backing, focusing on addressing unmet medical needs in oncology and beyond [6][88]

Summary of C4 Therapeutics FY Conference Call Company Overview - C4 Therapeutics is a targeted protein degradation company focused on developing a sustainable pipeline of medicines, particularly in oncology [2][3] - The company has a validated clinical oncology portfolio, including cemsidomide, an IKZF1/3 degrader [2] Key Developments and Milestones - C4 Therapeutics completed a financing round in October 2025, providing runway through the end of 2028 [3] - The MOMENTUM Phase II study has started enrollment, with patients already dosed [4] - A Phase 1b study in combination with elranatamab is expected to start next quarter [4] - The company anticipates having registrational data from the MOMENTUM study by 2028, along with the first NDA submission [5] Cemsidomide Insights - Cemsidomide is positioned as a best-in-class IKZF1/3 degrader, with a competitive efficacy profile compared to other drugs in the same class [7][8] - The drug has shown a response rate of 36% across all doses in Phase I, with a peak response rate of 53% at the highest dose [33] - Cemsidomide has a favorable safety profile, with only 6% of patients requiring dose reductions due to treatment-related adverse events [13] Market Opportunity - The myeloma market is large and growing, with an estimated peak revenue opportunity of $2.5 billion to $4 billion by 2030 [18] - There are approximately 22,000 patients in the fourth-line setting in the U.S. and EU, with expectations for growth as newer agents move into earlier lines of treatment [16] Combination Therapy Potential - The combination of cemsidomide with elranatamab (a BCMA BiTE) is expected to enhance efficacy, potentially bringing response rates on par with CAR T therapies [17][54] - The company is also exploring combinations with other agents like carfilzomib and CD38 [60] Discovery Strategy - C4 Therapeutics is focusing on inflammation, neuroinflammation, and neurodegeneration, with plans to develop first-in-class drugs against undruggable targets [19][20] - The company has identified three validated pathways and five novel targets for future development [20][21] Regulatory Considerations - The company is preparing for Accelerated Approval by ensuring high-quality data and independent evaluation of efficacy endpoints [44][45] - The recent FDA draft guidance on MRD negativity will be integrated into the Phase III trial design [48][49] Underappreciated Aspects - Cemsidomide is viewed as a foundational asset in myeloma care, with a best-in-class potential that is not fully appreciated by investors [65][66] - The unique mechanism of action and safety profile of cemsidomide may provide significant advantages in a competitive landscape [66][67]

Monte Rosa Therapeutics FY Conference Summary Company Overview - **Company**: Monte Rosa Therapeutics (NasdaqGS:GLUE) - **Industry**: Biotechnology, specifically focused on targeted protein degradation - **Established**: 7 years ago - **Core Technology**: Molecular glue degraders aimed at removing proteins in cells to develop medicines [2][3] Key Points and Arguments Clinical Programs and Data - **Clinical Trials**: Monte Rosa has three programs in the clinic, all producing positive clinical data. Plans to initiate at least one, and in some cases multiple, Phase 2 trials within the year [3][4] - **Collaboration Revenue**: Over $300 million in collaboration revenue generated in the last year, contributing to a strong balance sheet [4] - **NEK7 Degrader (MRT-8102)**: Focused on the NLRP3 inflammasome pathway, with significant data showing an 85% reduction in CRP levels in obese individuals with elevated CRP [8][9] - **CRP Normalization**: 94% of individuals in the study normalized their CRP levels, indicating strong efficacy compared to competitors [9][10] - **Safety Profile**: No toxicity concerns reported in Phase 1 studies, allowing for extended dosing in Phase 2 trials [11][28] Future Trials and Indications - **GFORCE-1 Study**: Expansion of the original Phase 1 trial into a Phase 2a study with additional dose levels to better understand the dose-response relationship [12][34] - **Oncology Focus**: Lead oncology project targets GSPT1, showing a 100% response rate in patients with androgen receptor mutations [14][45] - **Future Indications**: Plans to explore additional indications such as gout and hidradenitis, with a focus on self-development for certain conditions [35][39] Strategic Considerations - **Partnerships**: While ASCVD remains a top priority, the company is open to strategic partnerships for larger indications if necessary [41][42] - **Molecular Space**: Development of a second molecule to diversify the portfolio and enhance strategic options for future pricing and partnerships [42] Additional Important Insights - **VAV1 Target**: Selected for its potential in autoimmune diseases, with indications not yet disclosed but aligned with Novartis [52][53] - **Market Position**: Monte Rosa positions itself as a leader in targeted protein degradation, with a strong emphasis on innovative approaches to drug development [3][4] This summary encapsulates the key points discussed during the conference, highlighting Monte Rosa Therapeutics' strategic direction, clinical advancements, and future opportunities in the biotechnology sector.

Core Insights - C4 Therapeutics is advancing its investigational drug cemsidomide into later-stage clinical trials for multiple myeloma, with the first patient dosed in the Phase 2 MOMENTUM trial, which is designed for potential accelerated approval [1][2][12] - The company reported a strong financial position with cash, cash equivalents, and marketable securities totaling $297.1 million as of December 31, 2025, providing a runway to fund operations until the end of 2028 [1][10] - C4 Therapeutics is also focusing on expanding its research and discovery efforts in inflammation, neuroinflammation, and neurodegeneration, while maintaining collaborations in oncology [2][5] Financial Performance - Total revenue for the fourth quarter and full year ended December 31, 2025, was $11.0 million and $35.9 million, respectively, compared to $5.2 million and $35.6 million for the prior year periods, indicating a significant increase in quarterly revenue [6] - Research and development (R&D) expenses for the fourth quarter and full year were $25.0 million and $104.2 million, respectively, down from $32.5 million and $110.6 million in the prior year, primarily due to the completion of a clinical trial [7] - General and administrative (G&A) expenses for the fourth quarter and full year were $9.2 million and $36.2 million, respectively, compared to $10.4 million and $42.1 million in the prior year, reflecting a decrease in stock-based compensation [8] - The net loss for the fourth quarter and full year was $20.5 million and $105.0 million, respectively, compared to $34.6 million and $105.3 million for the prior year periods, with net loss per share improving to $0.18 and $1.27 [9] Clinical Development Updates - The Phase 2 MOMENTUM trial aims to evaluate cemsidomide in combination with dexamethasone in patients with relapsed/refractory multiple myeloma, with an expected enrollment of approximately 100 patients by Q1 2027 [5][12] - A Phase 1b trial of cemsidomide in combination with elranatamab is set to initiate in Q2 2026, following a collaboration agreement with Pfizer [5][13] - C4 Therapeutics plans to present further analysis of data from the completed Phase 1 trial of cemsidomide in mid-2026 and initiate an additional Phase 1b trial to evaluate cemsidomide with other anti-myeloma agents [5][14] Strategic Focus - The company is committed to advancing its discovery strategy, targeting areas with strong degrader rationale and first-in-class potential, particularly in inflammation and neurodegeneration [2][5] - C4 Therapeutics aims to optimize indication selection across its discovery portfolio and deliver at least one development candidate to a collaboration partner by the end of 2026 [14]